Ian Spatz
@rockcreekpolicyHealth care policy nerd; faculty @USCPrice, Snr. Advisor @ManattHealth, principal rockcreekpolicy. Health care is 2 words. Mastodon: @[email protected]
Similar User
@rachelcohrs
@InHealthPolicy
@john_wilkerson
@NicholasFlorko
@louiseradnofsky
@MarkMiller_DC
@tricia_neuman
@jenhab
@RodneyLWhitlock
@LorenAdler
@sarahL202
@maryagnescarey
@SarahKarlin
@ben_ippolito
@dwebbNPR
My take on the implications of the election on drug pricing. manatt.com/insights/newsl…
RFK Jr. on drug prices: "Level the playing field for Americans internationally on drug costs. ... Legislators should cap drug prices so that companies can’t charge Americans substantially more than Europeans pay." wsj.com/opinion/trump-…
Excellent perspective on the prospects of Cuban to disrupt Rx markets. Bottom line: not statnews.com/2024/07/29/mar…
Correlation between income & health well documented. But new study shows no causal link based on RCT of a guaranteed income program. People with more income used more health care but showed no better health across several measures. nber.org/papers/w32711
Important context on today's FTC PBM report. The FTC is not taking any action against any PBM. Some had expected enforcement action before November election. ftc.gov/reports/pharma…
A debate on how to do cost-effectiveness analysis but not about whether to do it. healthaffairs.org/content/forefr…
For some much needed perspective, the 2024 rebates appear to be less than one-tenth of a percent of all private health insurance spending (based on NHE #s). Not nothing but not a lot in the great scheme of things. Do I have my math correct @JaredOrtaliza ?? @KFF
NEW: Since 2012, about $12 billion in rebates have been issued to enrollees and employers. In 2024, insurers are estimated to issue $1 billion in rebates, bringing the total number up to $13 billion. @KFF @cynthiaccox Read more: kff.org/private-insura…
Will this plan come before or after his health care plan? Just asking for a friend. politico.com/news/2024/05/2… kffhealthnews.org/news/back-to-t…
Takeaways: (1) Network scope matters; (2) Employers are often terrible purchasers of insurance; (3) "middlemen" who deal with health system dysfunction (and make $ doing it) will get blamed. nytimes.com/2024/04/07/us/…
“… politicians can decide on ways to fix the dysfunctional drug pricing market and make sure patients have access.” But that’s the rub. What are those ways?
I watched #SOTU. Yes, pharma, they really hate you. And the Republicans do too. statnews.com/2024/03/08/bid…
A must read in @Health_Affairs from @PeterNeumann11 and @JoshuaPCohen1 at @TuftsCEVR Sadly, neither the pharm industry nor its critics have embraced value-based pricing perhaps in part bc of the valuation issues this article discusses. healthaffairs.org/content/forefr…
United States Trends
- 1. Browns 50 B posts
- 2. Jameis 18,6 B posts
- 3. Pam Bondi 187 B posts
- 4. #TNFonPrime 3.178 posts
- 5. #PITvsCLE 5.922 posts
- 6. Myles Garrett 5.408 posts
- 7. Tomlin 7.660 posts
- 8. Baylor 6.222 posts
- 9. Russ 31,6 B posts
- 10. Brandon Miller 4.191 posts
- 11. Njoku 5.352 posts
- 12. #DawgPound 4.446 posts
- 13. St. John 5.298 posts
- 14. Arthur Smith 1.635 posts
- 15. AFC North 3.387 posts
- 16. #HereWeGo 8.539 posts
- 17. Gaetz 957 B posts
- 18. #911onABC 27,3 B posts
- 19. Al Michaels N/A
- 20. Jeremy Roach 1.328 posts
Who to follow
-
Rachel Cohrs Zhang
@rachelcohrs -
InsideHealthPolicy
@InHealthPolicy -
John Wilkerson
@john_wilkerson -
Nicholas Florko
@NicholasFlorko -
Louise Radnofsky
@louiseradnofsky -
Mark Miller
@MarkMiller_DC -
Tricia Neuman
@tricia_neuman -
Jennifer Haberkorn
@jenhab -
Rodney L. Whitlock
@RodneyLWhitlock -
Loren Adler
@LorenAdler -
Sarah Lueck
@sarahL202 -
Mary Agnes Carey
@maryagnescarey -
Sarah Karlin-Smith
@SarahKarlin -
Ben Ippolito
@ben_ippolito -
Diane Webber
@dwebbNPR
Something went wrong.
Something went wrong.